Skip to main
CAH

Cardinal Health (CAH) Stock Forecast & Price Target

Cardinal Health (CAH) Analyst Ratings

Based on 12 analyst ratings
Buy
Strong Buy 33%
Buy 58%
Hold 8%
Sell 0%
Strong Sell 0%

Bulls say

Cardinal Health is poised for growth and success in the healthcare industry due to its competitive advantages such as their scaled distribution platform, partnerships with healthcare organizations, and strong presence in precision medicine. With investments in nuclear medicine, CDMO capabilities, and sustainability, along with their OptiFreight platform offering real-time visibility and cost savings, and a strong infrastructure for providing access to expensive therapies, Cardinal Health is well-positioned for future growth and earnings quality. Their strong performance in segments and expected growth in key financial metrics further reinforce their positive outlook as a leading pharmaceutical wholesaler in the US.

Bears say

Cardinal Health is facing a challenging competitive landscape, with reliance on a few major customers and the potential for high costs from legal issues. While potential growth opportunities in the nuclear medicine and biosimilar industries may provide some upside, the company's focus on expanding their distribution network and investing in automation may not be sufficient to overcome these obstacles. As a result, the negative outlook on their stock is justified, as there are significant risks that could impact their financial performance in the future.

Cardinal Health (CAH) has been analyzed by 12 analysts, with a consensus rating of Buy. 33% of analysts recommend a Strong Buy, 58% recommend Buy, 8% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Cardinal Health and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Cardinal Health (CAH) Forecast

Analysts have given Cardinal Health (CAH) a Buy based on their latest research and market trends.

According to 12 analysts, Cardinal Health (CAH) has a Buy consensus rating as of Aug 25, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $270.58, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $270.58, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Cardinal Health (CAH)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.